Sep 11, 2019 / 12:45PM GMT
David Ryan Lewis - Morgan Stanley, Research Division - MD
Let's go ahead and get going here. My name is David Lewis, Medical & Devices Analyst here at Morgan Stanley. Thanks for joining us here for our -- at least my first session of Day 3 of the Morgan Stanley Healthcare Conference. It's my pleasure to have with us here, Axonics, and their CEO, Ray Cohen. And we're just going to jump straight into the Q&A.
Questions and Answers:
David Ryan Lewis - Morgan Stanley, Research Division - MDThere has been some exciting news this week, Ray, we'll certainly get into. But given the approval for -- the first step approval for fecal incontinence with the system, I thought it'd be nice to start off and remind people, it's been a long time coming, waiting for this approval since the IPO. So maybe just talk a little bit about the market, just really briefly. How you see the size of -- that's one is fecal incontinence, but maybe we can talk about the overactive bladder market and sort of how that disease population is treated for sort of first, second, and
Trustpilot
